Iovance Biotherapeutics (IOVA) 10-Q7 Aug 182018 Q2 Quarterly reportFinancial data

Company Profile

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
Document And Entity Information - shares	Jun. 30, 2018	Jul. 31, 2018
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q2
Entity Registrant Name	IOVANCE BIOTHERAPEUTICS, INC.
Entity Central Index Key	1,425,205
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Trading Symbol	IOVA
Entity Common Stock, Shares Outstanding		95,592,169

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Current Assets
Cash and cash equivalents	$ 246,017	$ 145,373
Short-term investments	30,082	0
Prepaid expenses and other assets	3,682	3,917
Total Current Assets	279,781	149,290
Property and equipment, net	2,706	2,450
Long-term assets	2,264	3,633
Total Assets	284,751	155,373
Current Liabilities
Accounts payable	5,196	1,232
Accrued expenses	8,986	8,660
Total Current Liabilities	14,182	9,892
Commitments and contingencies (Note 9)
Stockholders' Equity
Common stock, $0.000041666 par value; 150,000,000 shares authorized, 92,741,672 and 73,164,914 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively	4	3
Accumulated other comprehensive loss	(3)	0
Additional paid-in capital	576,917	394,651
Accumulated deficit	(306,355)	(249,180)
Total Stockholders' Equity	270,569	145,481
Total Liabilities and Stockholders' Equity	284,751	155,373
Series A Convertible Preferred stock [Member]
Stockholders' Equity
Preferred stock, Value	0	0
Series B Convertible Preferred stock [Member]
Stockholders' Equity
Preferred stock, Value	$ 6	$ 7

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Common Stock, Par or Stated Value Per Share	$ 0.000041666	$ 0.000041666
Common Stock, Shares Authorized	150,000,000	150,000,000
Common Stock, Shares, Issued	92,741,672	73,164,914
Common Stock, Shares, Outstanding	92,741,672	73,164,914
Series A Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	17,000	17,000
Preferred Stock, Shares Issued	194	1,694
Preferred Stock, Shares Outstanding	194	1,694
Preferred Stock, Redemption Amount	$ 194	$ 194
Series B Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	11,500,000	11,500,000
Preferred Stock, Shares Issued	6,127,692	7,378,241
Preferred Stock, Shares Outstanding	6,127,692	7,378,241
Preferred Stock, Redemption Amount	$ 29,107	$ 29,107

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Revenues	$ 0	$ 0	$ 0	$ 0
Costs and expenses
Research and development expenses	24,551	18,647	44,463	34,240
General and administrative expenses	6,827	4,934	13,792	10,224
Total costs and expenses	31,378	23,581	58,255	44,464
Loss from operations	(31,378)	(23,581)	(58,255)	(44,464)
Other income
Interest income, net	718	204	1,080	403
Net Loss	$ (30,660)	$ (23,377)	$ (57,175)	$ (44,061)
Net Loss Per Common Share, Basic and Diluted	$ (0.34)	$ (0.37)	$ (0.65)	$ (0.71)
Weighted Average Common Shares Outstanding, Basic and Diluted	90,236	62,457	87,310	62,371

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Net Loss	$ (30,660)	$ (23,377)	$ (57,175)	$ (44,061)
Other comprehensive loss:
Unrealized loss on short-term investments	(3)	(2)	(3)	(29)
Comprehensive Loss	$ (30,663)	$ (23,379)	$ (57,178)	$ (44,090)

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Cash Flows from Operating Activities
Net loss	$ (57,175)	$ (44,061)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	453	464
Loss on disposal of assets	9	0
Accretion and amortization of discounts and premiums on investments	(1)	37
Stock-based compensation expense	9,326	6,589
Changes in assets and liabilities:
Prepaid expenses and other assets	1,604	(3,375)
Accounts payable	3,686	2,987
Accrued expenses	326	1,060
Net cash used in operating activities	(41,772)	(36,299)
Cash Flows from Investing Activities
Maturities of short-term investments	0	44,955
Purchase of short-term investments	(30,084)	0
Purchase of property and equipment	(440)	(823)
Net cash (used in) provided by investing activities	(30,524)	44,132
Cash Flows from Financing Activities
Tax payments related to shares withheld for vested restricted stock awards	(122)	(1,161)
Proceeds from the issuance of common stock upon exercise of warrants	4,141	250
Proceeds from the issuance of common stock upon exercise of options	6,828	646
Proceeds from the issuance of common stock, net	162,093	0
Net cash provided by (used in) financing activities	172,940	(265)
Net increase in cash and cash equivalents	100,644	7,568
Cash and Cash Equivalents, Beginning of Period	145,373	106,717
Cash and Cash Equivalents, End of Period	246,017	114,285
Supplemental disclosure of non-cash investing and financing activities:
Unrealized loss on short-term investments	(3)	(29)
Acquisitions of property and equipment included in accounts payable	(278)	(155)
Conversion of convertible preferred stock to common stock	$ 1	$ 0

GENERAL ORGANIZATION AND BUSINE

GENERAL ORGANIZATION AND BUSINESS	6 Months Ended
GENERAL ORGANIZATION AND BUSINESS	Jun. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GENERAL ORGANIZATION AND BUSINESS	NOTE 1. GENERAL ORGANIZATION AND BUSINESS Iovance Biotherapeutics, Inc. (the “Company,” “we,” “us” or “our”) is a biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. Our lead product candidate, lifileucel (LN-144) for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients’ tumors. TIL therapy is a platform technology that has already been studied for the treatment of metastatic melanoma and metastatic cervical cancer by the National Cancer Institute, or NCI. We are investigating the effectiveness and safety of TIL therapy for the treatment of metastatic melanoma, squamous cell carcinoma of the head and neck, cervical carcinoma, and metastatic non-small cell lung cancer, as well as other oncology indications. On June 1, 2017, the Company reincorporated to become a Company governed by Delaware corporation laws. On June 27, 2017, we changed our name to Iovance Biotherapeutics, Inc from Lion Biotechnologies, Inc. Basis of Presentation of Unaudited Condensed Consolidated Financial Information The unaudited condensed consolidated financial statements of the Company for the three and six months ended June 30, 2018 and 2017 have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and pursuant to the requirements for reporting on Form 10-Q and Regulation S-K. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. However, such information reflects all adjustments (consisting solely of normal recurring adjustments), which are, in the opinion of management, necessary for the fair presentation of the financial position and the results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full fiscal year. The balance sheet information as of December 31, 2017, was derived from the audited financial statements included in the Company's financial statements as of and for the year ended December 31, 2017 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 12, 2018. These financial statements should be read in conjunction with that report. Liquidity The Company is currently engaged in the development of therapeutics to fight cancer, specifically solid tumors. The Company currently does not have any commercial products and has not yet generated any revenues from its business. The Company currently does not anticipate that it will generate any revenues from the sale or licensing of any of its product candidates during the 12 months from the date these financial statements are issued. The Company has incurred a net loss of $57.2 million for the six months ended June 30, 2018 and used $41.8 million of cash in our operating activities during the six months ended June 30, 2018. In January 2018, the Company closed an underwritten public offering of 15,000,000 shares of the Company’s common stock at a public offering price of $11.50 per share, before underwriting discounts, which included 1,956,521 shares issued upon the exercise in full by the underwriter of its option to purchase additional shares at the public offering price less the underwriting discount. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by the Company, were $172.5 million, with net proceeds to the Company of approximately $162.0 million. For the six months ended June 30, 2018, the Company received $11.0 million from the exercise of stock options and warrants to purchase common stock. As of June 30, 2018, we had $246.0 million of cash and cash equivalents and $30.1 million in short-term investments. The Company expects to further increase its research and development activities, which will increase the amount of cash used during the remainder of 2018 and beyond. Specifically, the Company expects continued spending on clinical trials, continued and expansion of manufacturing activities, higher payroll expenses as the Company increases its professional and scientific staff and research and development activities. Based on the funds the Company has available as of the date these financial statements are issued, the Company believes that it has sufficient capital to fund its anticipated operating expenses for at least seven quarters from the date that these financial statements are issued. Concentrations of Risk We are subject to credit risk from our portfolio of cash equivalents and short-term investments. Under our investment policy, we limit amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. We are not exposed to any significant concentrations of credit risk from these financial instruments. The goals of our investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Jun. 30, 2018
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES	NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Cash, Cash Equivalents, and Short-term Investments The Company’s cash and cash equivalents include cash demand deposits and short-term investments with original maturities of three months or less when purchased. The Company's short-term investments are classified as “available-for-sale”. The Company includes these investments in current assets and carries them at fair value. Unrealized gains and losses on available-for-sale securities are included in accumulated other comprehensive loss. The cost of debt securities is adjusted for the amortization of premiums and accretion of discounts to maturity. Such amortization and accretion are included in interest expense and income. Gains and losses on securities sold are recorded based on the specific identification method and are included in interest income in the condensed consolidated statement of operations. We have not incurred any realized gains or losses from sales of securities to date. Loss per Share Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss by the sum of the weighted average number of shares of common stock outstanding and the dilutive common stock equivalent shares outstanding during the period. The Company’s potentially dilutive common stock equivalent shares, which include incremental common shares issuable upon (i) the exercise of outstanding stock options and warrants (ii) vesting of restricted stock units and restricted stock awards, and (iii) conversion of preferred stock, are only included in the calculation of diluted net loss per share when their effect is dilutive. At June 30, 2018 and 2017, the following outstanding common stock equivalents have been excluded from the calculation of net loss per share because their impact would be anti-dilutive. June 30, 2018 2017 Stock options 6,837,817 6,845,580 Warrants 4,644,706 6,466,216 Series A Convertible Preferred Stock* 97,000 847,000 Series B Convertible Preferred Stock* 6,127,692 7,946,673 Restricted stock awards - 2,917 Restricted stock units 91,665 137,500 17,798,880 22,245,886 * on an as-converted basis The dilutive effect of potentially dilutive securities is reflected in diluted earnings per common share by application of the treasury stock method. Under the treasury stock method, an increase in the fair market value of the Company's common stock can result in a greater dilutive effect from potentially dilutive securities. Fair Value Measurements Under Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, Fair Value Measurements and Disclosures, fair value is defined as the price at which an asset could be exchanged or a liability transferred in a transaction between knowledgeable, willing parties in the principal or most advantageous market for the asset or liability. Where available, fair value is based on observable market prices or parameters or derived from such prices or parameters. Where observable prices or parameters are not available, valuation models are applied. Assets and liabilities recorded at fair value in our financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities, are as follows: Level 1—Inputs are unadjusted, quoted prices in active markets for identical assets at the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 2—Are inputs, other than quoted prices included in Level 1, that are either directly or indirectly observable for the asset or liability through correlation with market data at the reporting date and for the duration of the instrument’s anticipated life. The fair valued assets we held and have held are generally assessed under Level 2 were corporate bonds and commercial paper. We utilize third party pricing services in developing fair value measurements where fair value is based on valuation methodologies such as models using observable market inputs, including benchmark yields, reported trades, broker/dealer quotes, bids, offers and other reference data. We use quotes from external pricing service providers and other on-line quotation systems to verify the fair value of investments provided by our third-party pricing service providers. We review independent auditor’s reports from our third-party pricing service providers particularly regarding the controls over pricing and valuation of financial instruments and ensure that our internal controls address certain control deficiencies, if any, and complementary user entity controls are in place. The Company does not have fair valued assets classified under Level 2. Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities and which reflect management’s best estimate of what market participants would use in pricing the asset or liability at the reporting date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. The Company does not have fair valued assets classified under Level 3. As of June 30, 2018, financial assets measured at fair value on a recurring basis are categorized in the table below based upon the lowest level of significant input to the valuations (in thousands): Assets at Fair Value as of June 30, 2018 Level 1 Level 2 Level 3 Total US treasury securities $ 18,898 $ - $ - $ 18,898 US government agency securities 11,184 - - 11,184 Total $ 30,082 $ - $ - $ 30,082 As of December 31, 2017, the Company had no financial assets measured at fair value on a recurring basis. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include valuation of short-term investments, the useful lives of property and equipment, accounting for potential liabilities, the valuation allowance associated with the Company’s deferred tax assets, and the assumptions made in valuing stock instruments issued for services. Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of Iovance Biotherapeutics, Inc. and its wholly-owned subsidiary, Iovance Biotherapeutics GmbH (formerly Lion Biotechnologies GmbH). All intercompany accounts and transactions have been eliminated. The U.S. dollar is the functional currency for all the Company's consolidated operations. Stock-Based Compensation The Company periodically grants stock options and warrants to employees and non-employees in non-capital raising transactions as compensation for services rendered. The Company accounts for stock option grants to employees based on the authoritative guidance provided by the FASB where the value of the award is measured on the date of grant and recognized over the vesting period. The Company accounts for stock option grants to non-employees in accordance with the authoritative guidance of the FASB where the value of the stock compensation is determined based upon the measurement date at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, option grants are immediately vested and the total stock-based compensation charge is recorded in the period of the measurement date. The fair value of the Company's common stock option grants is estimated using a Black-Scholes option pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the common stock options, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes option pricing model and based on actual experience. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future periods. The Company has in the past issued restricted shares of its common stock for share-based compensation programs. The Company measures the compensation cost with respect to restricted shares issued to employees based upon the estimated fair value of the equity instruments at the date of the grant, and is recognized as expense over the period which an employee is required to provide services in exchange for the award. The fair value of restricted stock units is based on the closing price of the Company’s common stock on the grant date. Total stock-based compensation expenses related to all our stock-based awards were recorded on the statements of operations as follows (in thousands): Three Months Ended June 30, Six Months Ended 2018 2017 2018 2017 Research and development $ 2,381 $ 1,742 $ 4,381 $ 2,992 General and administrative 2,841 1,551 4,945 3,597 Total stock-based compensation expenses $ 5,222 $ 3,293 $ 9,326 $ 6,589 Total stock-based compensation expenses broken down based on each individual instrument were as follows (in thousands): Three Months Ended June 30, Six Months Ended 2018 2017 2018 2017 Stock option expenses $ 5,155 $ 2,977 $ 9,192 $ 5,631 Restricted stock award expenses - 14 - 27 Restricted stock unit expenses 67 302 134 931 Total stock-based compensation expenses $ 5,222 $ 3,293 $ 9,326 $ 6,589 Preferred Stock The Company applies the accounting standards for distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. Conditionally redeemable preferred shares (including preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, preferred shares are classified as stockholders’ equity. Convertible Instruments The Company applies the accounting standards for derivatives and hedging and for distinguishing liabilities from equity when accounting for hybrid contracts that feature conversion options. The accounting standards require companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments per certain criteria. The criteria includes circumstances in which (i) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (ii) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (iii) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. The derivative is subsequently marked to market at each reporting date based on current fair value, with the changes in fair value reported in results of operations. Conversion options that contain variable settlement features such as provisions to adjust the conversion price upon subsequent issuances of equity or equity linked securities at exercise prices more favorable than that featured in the hybrid contract generally result in their bifurcation from the host instrument. The Company also records, when necessary, deemed dividends for the intrinsic value of the conversion options embedded in preferred stock based upon the difference between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the preferred stock. Recent Accounting Standards Not Yet Adopted In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which establishes a new lease accounting model for lessees. The updated guidance requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases, along with additional qualitative and quantitative disclosures. The amended guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018, with early adoption permitted. The Company plans to adopt this ASU on January 1, 2019. The Company is currently evaluating the impact of the adoption of this standard on its financial statements. However, the Company expects the adoption of this accounting guidance to result in an increase in lease assets and a corresponding increase in lease liabilities on its balance sheets. In June 2018, the FASB issued ASU No. 2018-07, Compensation- Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, which eliminates the separate accounting model for nonemployee share-based payment awards and generally requires companies to account for share-based payment transactions with nonemployees in the same way as share-based payment transactions with employees. The amended guidance is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company plans to adopt this ASU on January 1, 2019. The Company is currently evaluating the impact of the adoption of this standard on its financial statements. Subsequent Events Management evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the condensed consolidated financial statements. Reclassifications Certain amounts within the statements of operations for the prior periods have been reclassified to conform with the current period presentation. These reclassifications had no impact on the Company's previously reported financial position or cash flows for any of the periods presented.

CASH EQUIVALENTS AND SHORT-TERM

CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS	6 Months Ended
CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS	Jun. 30, 2018
Cash, Cash Equivalents, and Short-term Investments [Abstract]
CASH AND CASH EQUIVALENTS	NOTE 3. CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS Cash equivalents and short-term investments consist of the following (in thousands): June 30, December 31, 2018 2017 Cash equivalents - Money market funds $ 68,956 $ 91,281 Cash equivalents – US government agency securities 10,977 - Cash equivalents total $ 79,933 $ 91,281 Cash equivalents in the tables above exclude cash demand deposits of $166.1 million and $54.1 million as of June 30, 2018 and December 31, 2017, respectively. June 30, December 31, 2018 2017 Short-term Investments US treasury securities $ 18,898 $ - US government agency securities 11,184 - Short-term investments total $ 30,082 $ - The cost and fair value of cash equivalents and short-term investments at June 30, 2018 and December 31, 2017 were as follows (in thousands): Gross Gross Unrealized Unrealized As of June 30, 2018 Cost Accretion Gains Losses Fair Value $ 68,956 $ $ - $ - $ 68,956 22,161 1 - (1 ) 22,161 18,900 1 (2 ) 18,898 $ 110,016 $ 2 $ - $ (3 ) $ 110,015 Gross Gross Unrealized Unrealized As of December 31, 2017 Cost Gains Losses Fair Value Money market funds $ 91,281 $ - $ - $ 91,281 Total $ 91,281 $ - $ - $ 91,281 Unrealized gains and losses are included in accumulated other comprehensive loss. All short-term investments held by the Company as of June 30, 2018 have a maturity of less than one year.

BALANCE SHEET COMPONENTS

BALANCE SHEET COMPONENTS	6 Months Ended
BALANCE SHEET COMPONENTS	Jun. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BALANCE SHEET COMPONENTS	NOTE 4. BALANCE SHEET COMPONENTS Accrued expenses consist of the following (in thousands): June 30, December 31, 2018 2017 Accrued payroll and employee related expenses $ 2,613 $ 2,613 Legal and related services 552 935 Clinical related 3,920 3,310 Manufacturing related 1,150 876 Deferred rent 363 430 Accrued other 388 496 $ 8,986 $ 8,660

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	6 Months Ended
STOCKHOLDERS' EQUITY	Jun. 30, 2018
Stockholders' Equity Note [Abstract]
STOCKHOLDERS' EQUITY	NOTE 5. STOCKHOLDERS’ EQUITY Public Offering In January 2018, the Company closed an underwritten public offering of 15,000,000 shares of the Company’s common stock at a public offering price of $11.50 per share, before underwriting discounts, which included 1,956,521 shares issued upon the exercise in full by the underwriter of its option to purchase additional shares at the public offering price less the underwriting discount. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and other offering expenses payable by the Company, are $172.5 million, with net proceeds to the Company of $162.0 million. Preferred stock The Company’s certificate of incorporation authorizes the issuance of up to 50,000,000 shares of “blank check” preferred stock. At June 30, 2018 and December 31, 2017, 17,000 shares have been designated as Series A Convertible Preferred Stock and 11,500,000 shares have been designated as Series B Preferred Stock, which are now convertible into common stock (“Series B Convertible Preferred Stock”). Series A Convertible Preferred Stock A total of 17,000 shares of Series A Convertible Preferred Stock have been authorized for issuance under the Certificate of Designation of Preferences and Rights of Series A Convertible Preferred Stock. The shares of Series A Convertible Preferred Stock have a stated value of $1,000 per share and are initially convertible into shares of common stock at a price of $2.00 per share, subject to adjustment. The Series A Convertible Preferred Stock may, at the option of each investor, be converted into fully paid and non-assessable shares of common stock. The holders of shares of Series A Convertible Preferred Stock do not have the right to vote on matters that come before stockholders. In the event of any dissolution or winding up of the Company, proceeds shall be paid pari passu among the holders of the shares of common stock and preferred stock, pro rata based on the number of shares held by each holder. The Company may not declare, pay or set aside any dividends on shares of capital stock of the Company (other than dividends on shares of common stock payable in shares of common stock) unless the holders of the Series A Convertible Preferred Stock shall first receive an equal dividend on each outstanding share of Series A Convertible Preferred Stock. The common shares issued were determined on a formula basis of 500 common shares for each share of Series A Convertible Preferred Stock converted. During the six months ended June 30, 2018, 1,500 shares of Series A Convertible Preferred Stock were converted into 750,000 shares of common stock. At June 30, 2018, 194 shares of Series A Convertible Preferred Stock remained outstanding. Series B Convertible Preferred Stock A total of 11,500,000 shares of Series B Convertible Preferred Stock are authorized for issuance under the Company’s Series B Certificate of Designation of Rights, Preferences and Privileges of Series B Convertible Preferred Stock. The shares of Series B Convertible Preferred Stock have a stated value of $4.75 per share and are convertible into shares of the Company’s common stock at an initial conversion price of $4.75 per share. Holders of the Series B Convertible Preferred Stock are entitled to dividends on an as-if-converted basis in the same form as any dividends actually paid on shares of the Company’s Series A Convertible Preferred Stock or the Company’s common stock. So long as any Series B Convertible Preferred Stock remains outstanding, the Company may not redeem, purchase or otherwise acquire any material amount of our Series A Convertible Preferred Stock or any securities junior to the Series B Convertible Preferred Stock. During the six months ended June 30, 2018, 1,250,549 shares of Series B Convertible Preferred Stock were converted into 1,250,549 shares of common stock. At June 30, 2018, 6,127,692 shares of Series B Convertible Preferred Stock remained outstanding. Warrants The following table summarizes the Company’s stock warrant activity for the six months ended June 30, 2018: Weighted Weighted Shares Average Average Aggregate Under Exercise Remaining Intrinsic Warrants Price Life Value Outstanding at January 1, 2018 6,301,216 $ 2.51 $ 34,651,188 Issued - - Exercised (1,656,510 ) $ 2.50 Expired/Cancelled - - Outstanding at June 30, 2018 4,644,706 $ 2.51 0.4 years $ 47,830,172 The aggregate intrinsic value in the table reflects the total pretax intrinsic value (the difference between the Company’s closing stock price on the last day of the quarter ended June 30, 2018 and the exercise price of the warrants, multiplied by the number of in-the-money warrants) that would have been received by the warrant holders had all warrant holders exercised their warrants on June 30, 2018. The intrinsic value of the Company’s warrants changes based on the closing price of the Company’s common stock.

STOCK BASED COMPENSATION

STOCK BASED COMPENSATION	6 Months Ended
STOCK BASED COMPENSATION	Jun. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
STOCK BASED COMPENSATION	NOTE 6. STOCK BASED COMPENSATION Stock Plans As of October 14, 2011, the Company adopted the 2011 Equity Incentive Plan (the “2011 Plan”). Employees, directors, consultants and advisors of the Company are eligible to participate in the 2011 Plan. The 2011 Plan initially had 180,000 shares of common stock reserved for issuance in the form of incentive stock options, non-qualified options, common stock, and grant appreciation rights. The 2011 Plan was not approved by the Company’s stockholders within the required one-year period following its adoption and, accordingly, no incentive stock options can be granted under that plan. In August 2013, the Company’s Board of Directors and a majority of the Company’s stockholders approved an amendment to increase the number of shares available under the 2011 Plan from 180,000 shares to 1,700,000 shares, and an amendment to increase the number options or other awards that can be granted to any one person during a twelve (12) month period from 50,000 shares to 300,000 shares. The foregoing amendment to the 2011 Plan became effective in September 2013. On August 20, 2014, the Company’s Board of Directors amended the 2011 Plan to increase the number of shares available for issuance upon the exercise of stock options under the 2011 Plan from 1,700,000 to 1,900,000 shares, effective immediately. As of June 30, 2018, 542,490 shares were available for future grant under the 2011 Plan. On September 19, 2014, the Company’s Board of Directors (the “Board”) adopted the Iovance Biotherapeutics, Inc. 2014 Equity Incentive Plan (the “2014 Plan”). The 2014 Plan was approved by the Company’s stockholders at the annual meeting of stockholders held in November 2014. The 2014 Plan as approved by the stockholders authorized the issuance up to an aggregate of 2,350,000 shares of common stock. On April 10, 2015, the Board amended the 2014 Plan to increase the total number of shares that can be issued under the 2014 Plan to 4,000,000 shares of the Company’s common stock. The increase in shares available for issuance under the 2014 Plan was approved by the Company’s stockholders at the Company’s 2015 Annual Meeting of Stockholders in June 2015. On August 16, 2016, the Company’s stockholders approved the increase of the total number of shares that can be issued under the 2014 Plan from 4,000,000 shares to 9,000,000 shares of the Company’s common stock. At June 30, 2018, 906,390 shares were available for grant under the Company’s 2014 Plan. On April 22, 2018, the Board adopted the Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan (the “2018 Plan”). The 2018 Plan was approved by the Company’s stockholders at the annual meeting of stockholders held in June 2018. The 2018 Plan as approved by the stockholders authorized the issuance up to an aggregate of 6,000,000 shares of common stock reserved for issuance in the form of incentive (qualified) stock options, non-qualified options, common stock, stock appreciation rights, restricted stock awards, restricted stock units, other stock-based awards, other cash-based awards or any combination of the foregoing. At June 30, 2018, 6,000,000 shares of common stock were available for grant under the Company’s 2018 Plan. The Company anticipates granting the remaining shares under the 2011 and 2014 Plans prior to granting shares from the 2018 Plan. Restricted Stock Units On June 1, 2016, the Company entered into a restricted stock unit agreement with the Company’s Chief Executive Officer, Maria Fardis, Ph.D., pursuant to which the Company granted Dr. Fardis 550,000 non-transferrable restricted stock units at fair market value of $5.87 per share as an inducement of employment pursuant to the exception to The NASDAQ Global Market rules that generally require stockholder approval of equity incentive plans. The 550,000 restricted stock units vest in installments as follows: (i) 137,500 restricted stock units vested upon the first anniversary of the effective date of Dr. Fardis’ employment agreement; (ii) 275,000 restricted stock units vested upon the satisfaction of certain clinical trial milestones; and (iii) 137,500 restricted stock units vest in equal monthly installments over the 36-month period following the first anniversary of the effective date of Dr. Fardis’ employment, provided that Dr. Fardis has been continuously employed with the Company as of such vesting dates. As of June 30, 2018, 91,665 restricted stock units remained unvested. Stock-based compensation expenses for restricted stock units are measured based on the closing fair market value of the Company's common stock on the date of grant. The stock based compensation expenses relating to restricted stock units were $0.07 million and $0.3 million for the three months ended June 30, 2018 and 2017, respectively, and $0.1 million and $0.9 million for the six months ended June 30, 2018 and 2017, respectively, recorded as part of general and administrative expenses. As of June 30, 2018, there was $0.5 million of total unrecognized compensation expense related to the non-vested restricted stock units to be recognized over a period of 1.92 years. Stock Options The following table summarizes the Company’s stock options activity for the six months ended June 30, 2018: Weighted Weighted Number Average Average Aggregate of Exercise Remaining Intrinsic Options Price Contract Life Value Outstanding at January 1, 2018 6,072,368 $ 7.42 Granted 2,014,020 15.67 Exercised (895,153 ) 7.63 Expired/Forfeited (353,418 ) 10.53 Outstanding at June 30, 2018 6,837,817 $ 9.66 8.59 $ 28,425,872 Options exercisable at June 30, 2018 2,791,279 $ 7.84 7.85 $ 14,671,393 The Company recorded stock-based compensation costs related to options of $5.2 million and $3.0 million for the three months ended June 30, 2018 and 2017, respectively and $9.2 million and $5.6 million for the six months ended June 30, 2018 and 2017 respectively. As of June 30, 2018, there was $38.1 million of total unrecognized compensation expense related to the options to be recognized over a weighted average period of 2.19 years. The weighted-average grant date fair values per share of options granted under the 2011 and 2014 Plan were $15.26 and $6.83 for the six months ended June 30, 2018 and 2017, respectively. Options for 895,153 shares and 116,348 shared were exercised during the six months ended June 30, 2018 and 2017 with intrinsic value of $4.6 million and $0.2 million respectively. The aggregate intrinsic value in the table reflects the total pretax intrinsic value (the difference between the Company’s closing stock price on the last trading day of the quarter ended June 30, 2018 and the exercise price of the options, multiplied by the number of in-the-money stock options) that would have been received by the option holders had all option holders exercised their options on June 30, 2018. The intrinsic value of the Company’s stock options changes based on the closing price of the Company’s common stock. The fair value of each option issued during the six months ended June 30, 2018 and 2017 was estimated at the date of grant using the Black-Scholes valuation model. The weighted average assumptions used in the Black-Scholes calculation are presented below: Six months ended June 30, Assumptions: 2018 2017 Expected term (years) 5.13 – 6.50 5.13 – 6.50 Expected volatility 167.54% – 200.28% 190.46% – 209.69% Risk-free interest rate 2.27% – 2.97% 1.77% – 2.34% Expected dividend yield 0% 0%

LICENSES AND AGREEMENTS

LICENSES AND AGREEMENTS	6 Months Ended
LICENSES AND AGREEMENTS	Jun. 30, 2018
Licenses And Agreements [Abstract]
LICENSES AND AGREEMENTS	NOTE 7. LICENSES AND AGREEMENTS National Institutes of Health (NIH) and the National Cancer Institute (NCI) Cooperative Research and Development Agreement (CRADA) In August 2011, the Company signed a five-year CRADA with the NCI to work with Dr. Steven Rosenberg on developing adoptive cell immunotherapies that are designed to destroy metastatic melanoma cells using a patient’s tumor infiltrating lymphocytes. In January 2015, the Company executed an amendment (the “Amendment”) to the CRADA to include four new indications. As amended, in addition to metastatic melanoma, the CRADA included the development of TIL therapy for the treatment of patients with bladder, lung, triple-negative breast, and Human Papilloma Virus (“HPV”)-associated cancers. In August 2016, the NCI and the Company entered a second amendment to the CRADA. The principal changes effected by the second amendment included (i) extending the term of the CRADA by another five years to August 2021, and (ii) modifying the focus on the development of unmodified TIL as a stand-alone therapy or in combination with U.S. Food and Drug Administration (“FDA”) licensed products and commercially available reagents routinely used for adoptive cell therapy. The parties will continue the development of improved methods for the generation and selection of TIL with anti-tumor reactivity in metastatic melanoma, bladder, lung, breast, and HPV-associated cancers. Pursuant to the terms of the CRADA, we are currently required to make quarterly payments of $0.5 million to the NCI for support of research activities. To the extent the Company licenses patent rights relating to a TIL-based product candidate, the Company will be responsible for all patent-related expenses and fees, past and future, relating to the TIL-based product candidate. In addition, the Company may be required to supply certain test articles, including TIL, grown and processed under cGMP conditions, suitable for use in clinical trials, where the Company holds the investigational new drug application for such clinical trial. The extended CRADA has a five-year term expiring in August 2021. The Company or the NCI may unilaterally terminate the CRADA for any reason or for no reason at any time by providing written notice at least 60 days before the desired termination date. The Company recorded costs associated with the CRADA of $0.5 million for the three months ended June 30, 2018 and 2017 and $1.0 million for the six months ended June 30, 2018 and 2017 as research and development expenses. Patent License Agreement Related to the Development and Manufacture of TIL Effective October 5, 2011, the Company entered into a Patent License Agreement (the “Patent License Agreement”) with the National Institutes of Health, an agency of the United States Public Health Service within the Department of Health and Human Services (NIH), which Patent License Agreement was subsequently amended on February 9, 2015 and October 2, 2015. Pursuant to the Patent License Agreement as amended, the NIH granted the Company licenses, including exclusive, co-exclusive, and non-exclusive licenses, to certain technologies relating to autologous tumor infiltrating lymphocyte adoptive cell therapy products for the treatment of metastatic melanoma, lung, breast, bladder and HPV-positive cancers. The Patent License Agreement requires the Company to pay royalties based on a percentage of net sales (which percentage is in the mid-single digits), a percentage of revenues from sublicensing arrangements, and lump sum benchmark royalty payments on the achievement of certain clinical and regulatory milestones for each of the various indications and other direct costs incurred by the NIH pursuant to the agreement. Exclusive Patent License Agreement Related to TIL Selection On February 10, 2015, the Company entered into an Exclusive Patent License Agreement (the “Exclusive Patent License Agreement”) with the NIH under which the Company received an exclusive license to the NIH’s rights to patent-pending technologies related to methods for improving adoptive cell therapy through more potent and efficient production of TIL from melanoma tumors by selecting for T-cell populations that express various inhibitory receptors. Unless terminated sooner, the license shall remain in effect until the last licensed patent right expires. Under the Exclusive Patent License Agreement, the Company agreed to pay customary royalties based on a percentage of net sales of a licensed product (which percentage is in the mid-single digits), a percentage of revenues from sublicensing arrangements, and lump sum benchmark payments upon the successful completion of clinical studies involving licensed technologies, the receipt of the first FDA approval or foreign equivalent for a licensed product or process resulting from the licensed technologies, the first commercial sale of a licensed product or process in the United States, and the first commercial sale of a licensed product or process in any foreign country. H. Lee Moffitt Cancer Center Research Collaboration and Clinical Grant Agreements with Moffitt In December 2016, the Company entered into a new three-year Sponsored Research Agreement with H. Lee Moffitt Cancer Center (“Moffitt”). At the same time, the Company entered into a clinical grant agreement with Moffitt to support an ongoing clinical trial at Moffitt that combines TIL therapy with nivolumab for the treatment of patients with metastatic melanoma. In June 2017, the Company entered into a second clinical grant agreement with Moffitt to support a new clinical trial at Moffitt that combines TIL therapy with nivolumab for the treatment of patients with non-small cell lung cancer, under which the Company obtained a non-exclusive, royalty-free license to any new Moffitt inventions made in the performance of the agreement. Under both of the clinical grant agreements with Moffit, the Company has non-exclusive rights to clinical data arising from the respective clinical trials. The Company recorded costs associated with Moffitt of $1.0 million and $1.7 million for the three months ended June 30, 2018 and 2017, respectively, and $1.6 million and $2.3 million for the six months ended June 30, 2018 and 2017, respectively, as research and development expenses. Exclusive License Agreements with Moffitt The Company entered into a license agreement with Moffitt (the “First Moffitt License”), effective as of June 28, 2014, under which the Company received a world-wide license to Moffitt’s rights to patent-pending technologies related to methods for improving TIL for adoptive cell therapy using toll-like receptor agonists. Unless earlier terminated, the term of the license extends until the earlier of the expiration of the last issued patent related to the licensed technology or 20 years after the effective date of the license agreement. Pursuant to the First Moffitt License, the Company paid an upfront licensing fee in the amount of $0.1 million. A patent issuance fee will also be payable under the First Moffitt License, upon the issuance of the first U.S. patent covering the subject technology. In addition, the Company agreed to pay milestone license fees upon completion of specified milestones, customary royalties based on a specified percentage of net sales (which percentage is in the low single digits) and sublicensing payments, as applicable, and annual minimum royalties beginning with the first sale of products based on the licensed technologies, which minimum royalties will be credited against the percentage royalty payments otherwise payable in that year. The Company will also be responsible for all costs associated with the preparation, filing, maintenance and prosecution of the patent applications and patents covered by the First Moffitt License related to the treatment of any cancers in the United States, Europe and Japan and in other countries designated by the Company in agreement with Moffitt. The Company entered into a license agreement with Moffitt effective as of May 7, 2018 (the “Second Moffitt License”), under which the Company received a license to Moffitt’s rights to patent-pending technologies related to the use of 4-1BB agonists in conjunction with TIL manufacturing processes and therapies. Pursuant to the Second Moffitt License, the Company paid an upfront licensing fee in the amount of $0.1 million for the three months ended June 30, 2018. An annual license maintenance fee will be also payable commencing on the first anniversary of the effective date. In addition, the Company agreed to pay an annual commercial use payment for each indication for which a first sale has occurred, which in the aggregate amounts to up to $0.4 million a year. PolyBioCept and Karolinska University Hospital PolyBioCept Exclusive and Co-Exclusive License Agreement On September 14, 2016, the Company entered into an exclusive and co-exclusive license agreement (the “PolyBioCept Agreement”) with PolyBioCept AB, a corporation organized under the laws of Sweden (“PolyBioCept”). PolyBioCept has filed two patent applications with claims related to a cytokine cocktail for use in expansion of lymphocytes, one of which has been abandoned. Under the PolyBioCept Agreement, the Company received the exclusive right and license to PolyBioCept’s intellectual property to develop, manufacture, market and genetically engineer TIL produced by expansion, selection and enrichment using a proprietary cytokine cocktail. The Company also received a co-exclusive license (with PolyBioCept) to develop, manufacture and market genetically engineered TIL under the same intellectual property. The licenses are for the use in all cancers and are worldwide in scope, with the exception that the uses in melanoma are not included for certain countries of the former Soviet Union. The Company paid PolyBioCept a total of $2.5 million as an up-front exclusive license payment. The Company will also have to make additional milestone payments to PolyBioCept under the PolyBioCept Agreement if, and when, (i) certain product development milestones are achieved, (ii) certain regulatory approvals have been obtained from the FDA and/or the European Medicines Agency, and (iii) certain product sales targets are achieved. The milestone payments will be payable both in cash (U.S. dollars) and in shares of the Company’s common stock. If all of the foregoing product development, regulatory approval and sales milestone payments are met, the Company will have to pay PolyBioCept an additional $8.7 million and will have to issue to PolyBioCept a total 2,219,376 shares of unregistered common stock. In addition to these potential payments, the Company reimbursed PolyBioCept up to $0.2 million in expenses related to the transfer of know-how and paid PolyBioCept $0.1 million as a clinical trials management fee. The PolyBioCept Agreement has an initial term of 30 years and may be extended for additional five-year periods. During the three and six months ended June 30, 2018 and 2017 the Company recorded zero and $0.2 million associated with the PolyBioCept Agreement, respectively, as research and development expenses. Karolinska University Hospital and Karolinska Institute Agreements In connection with the execution of the PolyBioCept Agreement, the Company also (i) entered into a clinical trials agreement with the Karolinska University Hospital to conduct clinical trials in glioblastoma and pancreatic cancer at the Karolinska University Hospital, and (ii) agreed to enter into a sponsored research agreement with the Karolinska Institute for the research of the cytokine cocktail in additional indications. In the year ended December 31, 2016, the Company paid Karolinska University Hospital $1.6 million under the clinical trials agreement to conduct the clinical trials. As of April 9, 2018, the Company terminated the clinical trials agreement with the Karolinska University Hospital. In June 2018, the Company received a refund of $1.6 million from Karolinska, which resulted in a reversal of prior period expense and a credit of $0.4 million in the condensed consolidated statement of operations for the three and six months ended June 30, 2018. M.D. Anderson Cancer Center Strategic Alliance Agreement On April 17, 2017, the Company entered into a Strategic Alliance Agreement (the “SAA”) with M.D. Anderson Cancer Center (“M.D. Anderson”) under which the Company and M.D. Anderson agreed to conduct clinical and preclinical research studies. The Company agreed in the SAA to provide total funding not to exceed approximately $14.2 million for the performance of the multi-year studies under the SAA. In return, the Company will acquire all rights to inventions resulting from the studies and has been granted a non-exclusive, sub-licensable, royalty-free, and perpetual license to specified background intellectual property of M.D. Anderson reasonably necessary to exploit, including the commercialization thereof. The Company has also been granted certain rights in clinical data generated by M.D. Anderson outside of the clinical trials to be performed under the SAA. The SAA’s term shall continue in effect until the later of the fourth anniversary of the SAA or the completion or termination of the research and receipt by us of all deliverables due from M.D. Anderson thereunder. In May 2017, the Company paid $1.4 million under this agreement. The Company recorded $0.1 million associated with the M.D. Anderson SAA for the three and six months ended June 30, 2018. No costs were recorded for the same periods in 2017. MedImmune In December 2015, the Company entered into a collaboration agreement (the “MedImmune Agreement”) with MedImmune, the global biologics research and development arm of AstraZeneca (“MedImmune”), to conduct clinical and preclinical research in immuno-oncology. Under the MedImmune Agreement, the Company will fund and conduct at least one clinical trial combining MedImmune's PD-L1 inhibitor, durvalumab, with TIL for the treatment of patients. MedImmune will supply durvalumab for the clinical trials. The purpose of the studies is to establish a dosing regimen for this combination therapy and assess its safety and efficacy. WuXi Apptech, Inc. (“WuXi”) In November 2016, the Company entered into a three-year manufacturing and services agreement (“MSA”) with WuXi pursuant to which WuXi agreed to provide manufacturing and other services. Under the agreement, the Company entered into two statements of work for two cGMP manufacturing suites to be established and operated by WuXi for the Company, one of the suites is expected to be capable of being used for the commercial manufacture of our products. The statements of work for each facility include a fixed component to reserve a dedicated suite and a variable component, mainly labor and materials used during the manufacturing process. The fee payable under the first statement of work for the use of one of the manufacturing suites during the first year of the agreement, including the fees for the necessary personnel, was $2.5 million. The second statement of work, under which WuXi agreed to establish and operate a second, dedicated facility for a late stage/commercial manufacturing cGMP suite requires the Company to pay approximately $5.85 million during the first year of the agreement. The Company and WuXi have extended the term of the related statements of work until May 2020. The Company recorded costs associated with agreements with WuXi of $3.3 million for the three months ended June 30, 2018 and 2017, respectively, and $6.0 million and $7.5 million for the six months ended June 30, 2018 and 2017, respectively, as research and development expenses.

LEGAL PROCEEDINGS

LEGAL PROCEEDINGS	6 Months Ended
LEGAL PROCEEDINGS	Jun. 30, 2018
Loss Contingency [Abstract]
LEGAL PROCEEDINGS	NOTE 8. LEGAL PROCEEDINGS Class Action Lawsuit and Derivative Lawsuits In the Matter of Certain Stock Promotion Leonard DeSilvio v. Lion Biotechnologies, Inc., et al., (Amra Kuc vs. Lion Biotechnologies, Inc., et al., In the Matter of Certain Stock Promotions Kuc Kuc Jay Rabkin v. Lion Biotechnologies, Inc., et al., In the Matter of Certain Stock Promotions On December 15, 2017, a purported stockholder derivative complaint was filed by plaintiff Kevin Fong on behalf of the Company, against the Company, as nominal defendant, and certain of the Company’s current and former officers and directors, and others, as defendants, in the U.S. District Court for the District of Delaware (case no. 1:17-cv-1806). The complaint alleges breaches of fiduciary duties, unjust enrichment, and violations of Section 14(a) of the Securities Exchange Act of 1934 and Rule 14a-9 promulgated thereunder arising from the SEC’s investigation in the In the Matter of Certain Stock Promotions On March 28, 2018, a purported stockholder derivative complaint was filed by plaintiff Nazeer Khaleeluddin on behalf of the Company, against the Company, as nominal defendant, and certain of the Company’s current and former officers and directors, and others, as defendants, in the U.S. District Court for the District of Delaware (case no. 1:18-cv-00469). The complaint alleges, among other things, violations of securities law, breach of fiduciary duty, aiding and abetting, waste of corporate assets, and unjust enrichment. The complaint is based on claims arising from the SEC’s investigation in the In the Matter of Certain Stock Promotions We intend to vigorously defend against the foregoing complaints. Based on the very early stage of the litigation, it is not possible to estimate the amount or range of possible loss that might result from an adverse judgment or a settlement of these matters. Solomon Capital, LLC. Solomon Capital, LLC, Solomon Capital 401(K) Trust, Solomon Sharbat and Shelhav Raff v. Lion Biotechnologies, Inc. was filed by Solomon Capital, LLC, Solomon Capital 401(k) Trust, Solomon Sharbat and Shelhav Raff against the Company in the Supreme Court of the State of New York, County of New York (index no. 651881/2016). The plaintiffs allege that, between June and November 2012 they provided to the Company $0.1 million and that they advanced and paid on our behalf an additional $0.2 million. The complaint further alleges that the Company agreed to (i) provide them with promissory notes totaling $0.2 million, plus interest, (ii) issue a total of 111,425 shares to the plaintiffs (before the 1-for-100 reverse split of our common stock effected in March 2013), and (iii) allow the plaintiffs to convert the foregoing funds into our securities in the next transaction. The plaintiffs allege that they should have been able to convert their advances and payments into shares of the Company’s common stock in the restructuring that was affected in May 2013. Based on the foregoing, the plaintiffs allege causes for breach of contract and unjust enrichment and demand judgment against the Company in an unspecified amount exceeding $1.5 million, plus interest and attorneys’ fees. On June 3, 2016, the Company filed an answer and counterclaims in the lawsuit. In its counterclaims, the Company alleges that the plaintiffs misrepresented their qualifications to assist it in fundraising and that they failed to disclose that they were under investigation for securities laws violations. The Company is seeking damages in an amount exceeding $0.5 million and an order rescinding any and all agreements that the plaintiffs contend entitled them to obtain stock in the Company. On April 19, 2017, the court granted plaintiffs’ counsel’s motion to withdraw from the case. On May 25, 2017, plaintiffs filed a notice that they had hired new counsel. On June 7, 2017, the judge presiding over the case recused herself because of a conflict of interest arising from her relationship with plaintiffs’ new attorneys, and the case was subsequently assigned to a new judge. On April 20, 2018, the court held a hearing regarding plaintiff’s motion to dismiss certain counterclaims by the Company. The Company intends to vigorously defend the complaint and pursue its counterclaims. Litigation Involving Dr. Steven Fischkoff Steven Fischkoff v. Lion Biotechnologies, Inc. and Maria Fardis We intend to vigorously defend against Dr. Fischkoff’s lawsuit and pursue the Company’s counterclaims. Based on the very early stage of the litigation, it is not possible to estimate the amount or range of (i) a possible loss that might result from an adverse judgment or settlement of this action, or (ii) the potential recovery that might result from a favorable judgment or a settlement of this action. Other Matters. The Company may be involved, from time to time, in legal proceedings and claims arising in the ordinary course of its business. Such matters are subject to many uncertainties and outcomes are not predictable with assurance. The Company accrues amounts, to the extent they can be reasonably estimated, that it believes are adequate to address any liabilities related to legal proceedings and other loss contingencies that the Company believes will result in a probable loss. While there can be no assurances as to the ultimate outcome of any legal proceeding or other loss contingency involving the Company, management does not believe any pending matter will be resolved in a manner that would have a material adverse effect on the Company’s financial position, results of operations or cash flows.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
COMMITMENTS AND CONTINGENCIES	Jun. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 9. COMMITMENTS AND CONTINGENCIES Facilities Leases Tampa Lease In December 2014, the Company commenced a five-year non-cancellable operating lease with the University of South Florida Research Foundation for a 5,115-square foot facility located in Tampa, Florida. The facility is part of the University of South Florida research park and is used as the Company’s research and development facilities. The Company has the option to extend the lease term of this facility for an additional five-year period on the same terms and conditions, except that the base rent for the renewal term will be increased in accordance with the applicable consumer price index. In April 2015, the Company amended the original lease agreement to increase the rentable space to 6,043 square feet. In September 2016, the Company further increased the rentable space to 8,673 square feet. The per square foot cost and term of the lease were unchanged, and rent payments are approximately $20,000 per month. The lease expires in November 2019. San Carlos Lease On August 4, 2016, the Company entered into an agreement to lease 8,733 square feet in San Carlos, California. The term of the lease is 54 months subsequent to the commencement date and will expire in April 2021. Monthly lease payments are approximately $38,000. On April 28, 2017, the Company entered into a sublease agreement with Teradata US, Inc., pursuant to which the Company agreed to sublease certain office space located adjacent to the Company's headquarters in San Carlos, California. The space consists of approximately 11,449 rentable square feet in the building located in San Carlos, California and will expire on October 31, 2018. Monthly lease payments are approximately $26,000. New York Lease The Company leased office space in New York for a monthly rental of approximately $18,000 a month through July 2017. On June 5, 2017, the Company entered into an agreement whereby the Company will lease office space from August 1, 2017 to July 31, 2018 for approximately $9,000 a month. On April 20, 2018, the Company entered into an agreement to extend the lease term to January 31, 2019 for approximately $7,000 a month. The Company recognizes rental expense on the facilities on a straight-line basis over the lease term. Differences between the straight-line rent expense and rent payments are classified as deferred rent liability on the balance sheet. As of June 30, 2018, the Company's future minimum lease payments under non-cancelable operating leases are as follows (in thousands): Year Operating ‎ Lease Commitments 2018 (remaining six months) $ 501 2019 707 2020 495 2021 169 $ 1,872 Rent expense was $ million for the three months ended and , respectively, and was $ million for the six months ended and , respectively.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	6 Months Ended
RELATED PARTY TRANSACTIONS	Jun. 30, 2018
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 10. RELATED PARTY TRANSACTIONS Sanford J. Hillsberg was one of the Company’s directors until June 6, 2018. Mr. Hillsberg is an attorney at TroyGould PC. TroyGould PC rendered and continues to render legal services to the Company. The Company paid TroyGould PC $0.2 million for the three months ended June 30, 2018 and 2017, respectively, and $0.3 million and $0.4 million for the six months ended June 2018 and 2017, respectively. Mr. Hillsberg did not directly provide any legal services to the Company during the periods noted. As of June 30, 2018, no liability was owed to TroyGould PC related to legal services. On September 14, 2017, the Company entered into a three-year consulting agreement with Iain Dukes, D. Phil, the Chairman of the Company’s Board of Directors. As compensation for his consulting services, the Company granted Dr. Dukes a stock option to purchase up to 150,000 shares of the Company’s common stock, at an exercise price of $7.30 per share. Under the consulting agreement, Dr. Dukes agreed to provide the Company with services regarding business development opportunities, licensing transactions and technology acquisitions by the Company, and any such strategic initiatives appropriate for the Company that Dr. Dukes may identify. The granted stock options vest in 12 quarterly installments (with 1/12th of the option shares having vested on the date of grant). The vesting of the granted stock options will accelerate, and the entire award will become fully vested upon the closing of a significant licensing transaction, a material product acquisition, a material strategic transaction, or upon a change of control transaction. The Company recognized $0.2 million and $0.6 million of stock based compensation expenses relating to this consulting agreement for the three and six months ended June 30, 2018, respectively.

SUMMARY OF SIGNIFICANT ACCOUN17

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	Jun. 30, 2018
Accounting Policies [Abstract]
Cash, Cash Equivalents, and Short-term Investments	Cash, Cash Equivalents, and Short-term Investments The Company’s cash and cash equivalents include cash demand deposits and short-term investments with original maturities of three months or less when purchased. The Company's short-term investments are classified as “available-for-sale”. The Company includes these investments in current assets and carries them at fair value. Unrealized gains and losses on available-for-sale securities are included in accumulated other comprehensive loss. The cost of debt securities is adjusted for the amortization of premiums and accretion of discounts to maturity. Such amortization and accretion are included in interest expense and income. Gains and losses on securities sold are recorded based on the specific identification method and are included in interest income in the condensed consolidated statement of operations. We have not incurred any realized gains or losses from sales of securities to date.
Loss per Share	Loss per Share Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss by the sum of the weighted average number of shares of common stock outstanding and the dilutive common stock equivalent shares outstanding during the period. The Company’s potentially dilutive common stock equivalent shares, which include incremental common shares issuable upon (i) the exercise of outstanding stock options and warrants (ii) vesting of restricted stock units and restricted stock awards, and (iii) conversion of preferred stock, are only included in the calculation of diluted net loss per share when their effect is dilutive. At June 30, 2018 and 2017, the following outstanding common stock equivalents have been excluded from the calculation of net loss per share because their impact would be anti-dilutive. June 30, 2018 2017 Stock options 6,837,817 6,845,580 Warrants 4,644,706 6,466,216 Series A Convertible Preferred Stock* 97,000 847,000 Series B Convertible Preferred Stock* 6,127,692 7,946,673 Restricted stock awards - 2,917 Restricted stock units 91,665 137,500 17,798,880 22,245,886 * on an as-converted basis The dilutive effect of potentially dilutive securities is reflected in diluted earnings per common share by application of the treasury stock method. Under the treasury stock method, an increase in the fair market value of the Company's common stock can result in a greater dilutive effect from potentially dilutive securities.
Fair Value Measurements	Fair Value Measurements Under Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, Fair Value Measurements and Disclosures, fair value is defined as the price at which an asset could be exchanged or a liability transferred in a transaction between knowledgeable, willing parties in the principal or most advantageous market for the asset or liability. Where available, fair value is based on observable market prices or parameters or derived from such prices or parameters. Where observable prices or parameters are not available, valuation models are applied. Assets and liabilities recorded at fair value in our financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities, are as follows: Level 1—Inputs are unadjusted, quoted prices in active markets for identical assets at the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 2—Are inputs, other than quoted prices included in Level 1, that are either directly or indirectly observable for the asset or liability through correlation with market data at the reporting date and for the duration of the instrument’s anticipated life. The fair valued assets we held and have held are generally assessed under Level 2 were corporate bonds and commercial paper. We utilize third party pricing services in developing fair value measurements where fair value is based on valuation methodologies such as models using observable market inputs, including benchmark yields, reported trades, broker/dealer quotes, bids, offers and other reference data. We use quotes from external pricing service providers and other on-line quotation systems to verify the fair value of investments provided by our third-party pricing service providers. We review independent auditor’s reports from our third-party pricing service providers particularly regarding the controls over pricing and valuation of financial instruments and ensure that our internal controls address certain control deficiencies, if any, and complementary user entity controls are in place. The Company does not have fair valued assets classified under Level 2. Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities and which reflect management’s best estimate of what market participants would use in pricing the asset or liability at the reporting date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. The Company does not have fair valued assets classified under Level 3. As of June 30, 2018, financial assets measured at fair value on a recurring basis are categorized in the table below based upon the lowest level of significant input to the valuations (in thousands): Assets at Fair Value as of June 30, 2018 Level 1 Level 2 Level 3 Total US treasury securities $ 18,898 $ - $ - $ 18,898 US government agency securities 11,184 - - 11,184 Total $ 30,082 $ - $ - $ 30,082 As of December 31, 2017, the Company had no financial assets measured at fair value on a recurring basis.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include valuation of short-term investments, the useful lives of property and equipment, accounting for potential liabilities, the valuation allowance associated with the Company’s deferred tax assets, and the assumptions made in valuing stock instruments issued for services.
Principles of Consolidation	Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of Iovance Biotherapeutics, Inc. and its wholly-owned subsidiary, Iovance Biotherapeutics GmbH (formerly Lion Biotechnologies GmbH). All intercompany accounts and transactions have been eliminated. The U.S. dollar is the functional currency for all the Company's consolidated operations.
Stock-Based Compensation	Stock-Based Compensation The Company periodically grants stock options and warrants to employees and non-employees in non-capital raising transactions as compensation for services rendered. The Company accounts for stock option grants to employees based on the authoritative guidance provided by the FASB where the value of the award is measured on the date of grant and recognized over the vesting period. The Company accounts for stock option grants to non-employees in accordance with the authoritative guidance of the FASB where the value of the stock compensation is determined based upon the measurement date at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, option grants are immediately vested and the total stock-based compensation charge is recorded in the period of the measurement date. The fair value of the Company's common stock option grants is estimated using a Black-Scholes option pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the common stock options, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes option pricing model and based on actual experience. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future periods. The Company has in the past issued restricted shares of its common stock for share-based compensation programs. The Company measures the compensation cost with respect to restricted shares issued to employees based upon the estimated fair value of the equity instruments at the date of the grant, and is recognized as expense over the period which an employee is required to provide services in exchange for the award. The fair value of restricted stock units is based on the closing price of the Company’s common stock on the grant date. Total stock-based compensation expenses related to all our stock-based awards were recorded on the statements of operations as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Research and development $ 2,381 $ 1,742 $ 4,381 $ 2,992 General and administrative 2,841 1,551 4,945 3,597 Total stock-based compensation expenses $ 5,222 $ 3,293 $ 9,326 $ 6,589 Total stock-based compensation expenses broken down based on each individual instrument were as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Stock option expenses $ 5,155 $ 2,977 $ 9,192 $ 5,631 Restricted stock award expenses - 14 - 27 Restricted stock unit expenses 67 302 134 931 Total stock-based compensation expenses $ 5,222 $ 3,293 $ 9,326 $ 6,589
Preferred Stock	Preferred Stock The Company applies the accounting standards for distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. Conditionally redeemable preferred shares (including preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, preferred shares are classified as stockholders’ equity.
Convertible Instruments	Convertible Instruments The Company applies the accounting standards for derivatives and hedging and for distinguishing liabilities from equity when accounting for hybrid contracts that feature conversion options. The accounting standards require companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments per certain criteria. The criteria includes circumstances in which (i) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (ii) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (iii) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. The derivative is subsequently marked to market at each reporting date based on current fair value, with the changes in fair value reported in results of operations. Conversion options that contain variable settlement features such as provisions to adjust the conversion price upon subsequent issuances of equity or equity linked securities at exercise prices more favorable than that featured in the hybrid contract generally result in their bifurcation from the host instrument. The Company also records, when necessary, deemed dividends for the intrinsic value of the conversion options embedded in preferred stock based upon the difference between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the preferred stock.
Recent Accounting Standards	Recent Accounting Standards Not Yet Adopted In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which establishes a new lease accounting model for lessees. The updated guidance requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases, along with additional qualitative and quantitative disclosures. The amended guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018, with early adoption permitted. The Company plans to adopt this ASU on January 1, 2019. The Company is currently evaluating the impact of the adoption of this standard on its financial statements. However, the Company expects the adoption of this accounting guidance to result in an increase in lease assets and a corresponding increase in lease liabilities on its balance sheets. In June 2018, the FASB issued ASU No. 2018-07, Compensation- Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, which eliminates the separate accounting model for nonemployee share-based payment awards and generally requires companies to account for share-based payment transactions with nonemployees in the same way as share-based payment transactions with employees. The amended guidance is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company plans to adopt this ASU on January 1, 2019. The Company is currently evaluating the impact of the adoption of this standard on its financial statements.
Subsequent Events	Subsequent Events Management evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the condensed consolidated financial statements.
Reclassifications	Reclassifications Certain amounts within the statements of operations for the prior periods have been reclassified to conform with the current period presentation. These reclassifications had no impact on the Company's previously reported financial position or cash flows for any of the periods presented.

SUMMARY OF SIGNIFICANT ACCOUN18

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	6 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	Jun. 30, 2018
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	At June 30, 2018 and 2017, the following outstanding common stock equivalents have been excluded from the calculation of net loss per share because their impact would be anti-dilutive. June 30, 2018 2017 Stock options 6,837,817 6,845,580 Warrants 4,644,706 6,466,216 Series A Convertible Preferred Stock* 97,000 847,000 Series B Convertible Preferred Stock* 6,127,692 7,946,673 Restricted stock awards - 2,917 Restricted stock units 91,665 137,500 17,798,880 22,245,886 * on an as-converted basis
Schedule of Assets Measured at Fair Value	As of June 30, 2018, financial assets measured at fair value on a recurring basis are categorized in the table below based upon the lowest level of significant input to the valuations (in thousands): Assets at Fair Value as of June 30, 2018 Level 1 Level 2 Level 3 Total US treasury securities $ 18,898 $ - $ - $ 18,898 US government agency securities 11,184 - - 11,184 Total $ 30,082 $ - $ - $ 30,082
Schedule of Stock-Based Compensation	Total stock-based compensation expenses related to all our stock-based awards were recorded on the statements of operations as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Research and development $ 2,381 $ 1,742 $ 4,381 $ 2,992 General and administrative 2,841 1,551 4,945 3,597 Total stock-based compensation expenses $ 5,222 $ 3,293 $ 9,326 $ 6,589
Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan	Total stock-based compensation expenses broken down based on each individual instrument were as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Stock option expenses $ 5,155 $ 2,977 $ 9,192 $ 5,631 Restricted stock award expenses - 14 - 27 Restricted stock unit expenses 67 302 134 931 Total stock-based compensation expenses $ 5,222 $ 3,293 $ 9,326 $ 6,589

CASH EQUIVALENTS AND SHORT-TE19

CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS (Tables)	6 Months Ended
CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS (Tables)	Jun. 30, 2018
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Schedule of Cash, Money Market Funds and Short-Term Investments	Cash equivalents and short-term investments consist of the following (in thousands): June 30, December 31, 2018 2017 Cash equivalents - Money market funds $ 68,956 $ 91,281 Cash equivalents – US government agency securities 10,977 - Cash equivalents total $ 79,933 $ 91,281 Cash equivalents in the tables above exclude cash demand deposits of $166.1 million and $54.1 million as of June 30, 2018 and December 31, 2017, respectively. June 30, December 31, 2018 2017 Short-term Investments US treasury securities $ 18,898 $ - US government agency securities 11,184 - Short-term investments total $ 30,082 $ -
Unrealized Gain (Loss) on Investments [Table Text Block]	The cost and fair value of cash equivalents and short-term investments at June 30, 2018 and December 31, 2017 were as follows (in thousands): Gross Gross Unrealized Unrealized As of June 30, 2018 Cost Accretion Gains Losses Fair Value $ 68,956 $ $ - $ - $ 68,956 22,161 1 - (1 ) 22,161 18,900 1 (2 ) 18,898 $ 110,016 $ 2 $ - $ (3 ) $ 110,015 Gross Gross Unrealized Unrealized As of December 31, 2017 Cost Gains Losses Fair Value Money market funds $ 91,281 $ - $ - $ 91,281 Total $ 91,281 $ - $ - $ 91,281

BALANCE SHEET COMPONENTS (Table

BALANCE SHEET COMPONENTS (Tables)	6 Months Ended
BALANCE SHEET COMPONENTS (Tables)	Jun. 30, 2018
Property, Plant and Equipment [Abstract]
Schedule of Accrued Liabilities	Accrued expenses consist of the following (in thousands): June 30, December 31, 2018 2017 Accrued payroll and employee related expenses $ 2,613 $ 2,613 Legal and related services 552 935 Clinical related 3,920 3,310 Manufacturing related 1,150 876 Deferred rent 363 430 Accrued other 388 496 $ 8,986 $ 8,660

STOCKHOLDERS' EQUITY (Tables)

STOCKHOLDERS' EQUITY (Tables)	6 Months Ended
STOCKHOLDERS' EQUITY (Tables)	Jun. 30, 2018
Stockholders' Equity Note [Abstract]
Schedule of Stockholders' Equity Note, Warrants or Rights	The following table summarizes the Company’s stock warrant activity for the six months ended June 30, 2018: Weighted Weighted Shares Average Average Aggregate Under Exercise Remaining Intrinsic Warrants Price Life Value Outstanding at January 1, 2018 6,301,216 $ 2.51 $ 34,651,188 Issued - - Exercised (1,656,510 ) $ 2.50 Expired/Cancelled - - Outstanding at June 30, 2018 4,644,706 $ 2.51 0.4 years $ 47,830,172

STOCK BASED COMPENSATION (Table

STOCK BASED COMPENSATION (Tables)	6 Months Ended
STOCK BASED COMPENSATION (Tables)	Jun. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Status of Stock Options	The following table summarizes the Company’s stock options activity for the six months ended June 30, 2018: Weighted Weighted Number Average Average Aggregate of Exercise Remaining Intrinsic Options Price Contract Life Value Outstanding at January 1, 2018 6,072,368 $ 7.42 Granted 2,014,020 15.67 Exercised (895,153 ) 7.63 Expired/Forfeited (353,418 ) 10.53 Outstanding at June 30, 2018 6,837,817 $ 9.66 8.59 $ 28,425,872 Options exercisable at June 30, 2018 2,791,279 $ 7.84 7.85 $ 14,671,393
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The fair value of each option issued during the six months ended June 30, 2018 and 2017 was estimated at the date of grant using the Black-Scholes valuation model. The weighted average assumptions used in the Black-Scholes calculation are presented below: Six months ended June 30, Assumptions: 2018 2017 Expected term (years) 5.13 – 6.50 5.13 – 6.50 Expected volatility 167.54% – 200.28% 190.46% – 209.69% Risk-free interest rate 2.27% – 2.97% 1.77% – 2.34% Expected dividend yield 0% 0%

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	6 Months Ended
COMMITMENTS AND CONTINGENCIES (Tables)	Jun. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases	As of June 30, 2018, the Company's future minimum lease payments under non-cancelable operating leases are as follows (in thousands): Year Operating ‎ Lease Commitments 2018 (remaining six months) $ 501 2019 707 2020 495 2021 169 $ 1,872 Rent expense was $ million for the three months ended and , respectively, and was $ million for the six months ended and , respectively.

GENERAL ORGANIZATION AND BUSI24

GENERAL ORGANIZATION AND BUSINESS (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended
	Jan. 31, 2018	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Net Income (Loss) Attributable to Parent		$ (30,660)	$ (23,377)	$ (57,175)	$ (44,061)
Net Cash Provided by (Used in) Operating Activities				(41,772)	(36,299)
Proceeds from Issuance of Common Stock				162,093	0
Shares Issued, Price Per Share	$ 11.50
Available-for-sale Securities, Current		30,082		30,082		$ 0
Cash and Cash Equivalents, at Carrying Value		$ 246,017	$ 114,285	246,017	$ 114,285	$ 145,373	$ 106,717
Proceeds from Stock Options and Warrants Exercised				11,000
IPO [Member]
Stock Issued During Period, Shares, New Issues	15,000,000
Proceeds from Issuance of Common Stock	$ 162,000			$ 162,000
Shares Issued, Price Per Share	$ 11.50
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	1,956,521
Stock Issued During Period, Value, New Issues	$ 172,500

SUMMARY OF SIGNIFICANT ACCOUN25

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - shares		6 Months Ended
		Jun. 30, 2018	Jun. 30, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		17,798,880	22,245,886
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		6,837,817	6,845,580
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		4,644,706	6,466,216
Restricted Stock Awards [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		0	2,917
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		91,665	137,500
Series A Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	[1]	97,000	847,000
Series B Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	[1]	6,127,692	7,946,673

[1]	on an as-converted basis

SUMMARY OF SIGNIFICANT ACCOUN26

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) $ in Thousands	Jun. 30, 2018USD ($)
Assets, Fair Value Disclosure	$ 30,082
US Government agency securities [Member]
Assets, Fair Value Disclosure	11,184
US Treasury Securities [Member]
Assets, Fair Value Disclosure	18,898
Fair Value, Inputs, Level 1 [Member]
Assets, Fair Value Disclosure	30,082
Fair Value, Inputs, Level 1 [Member] \| US Government agency securities [Member]
Assets, Fair Value Disclosure	11,184
Fair Value, Inputs, Level 1 [Member] \| US Treasury Securities [Member]
Assets, Fair Value Disclosure	18,898
Fair Value, Inputs, Level 2 [Member]
Assets, Fair Value Disclosure	0
Fair Value, Inputs, Level 2 [Member] \| US Government agency securities [Member]
Assets, Fair Value Disclosure	0
Fair Value, Inputs, Level 2 [Member] \| US Treasury Securities [Member]
Assets, Fair Value Disclosure	0
Fair Value, Inputs, Level 3 [Member]
Assets, Fair Value Disclosure	0
Fair Value, Inputs, Level 3 [Member] \| US Government agency securities [Member]
Assets, Fair Value Disclosure	0
Fair Value, Inputs, Level 3 [Member] \| US Treasury Securities [Member]
Assets, Fair Value Disclosure	$ 0

SUMMARY OF SIGNIFICANT ACCOUN27

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost, Total	$ 5,222	$ 3,293	$ 9,326	$ 6,589
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost, Total	2,381	1,742	4,381	2,992
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost, Total	$ 2,841	$ 1,551	$ 4,945	$ 3,597

SUMMARY OF SIGNIFICANT ACCOUN28

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost	$ 5,222	$ 3,293	$ 9,326	$ 6,589
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost	5,155	2,977	9,192	5,631
Restricted Stock Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost	0	14	0	27
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost	$ 67	$ 302	$ 134	$ 931

CASH EQUIVALENTS AND SHORT-TE29

CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Short-term Investments
Cash Equivalents, at Carrying Value	$ 79,933	$ 91,281
Demand Deposits [Member]
Short-term Investments
Cash Equivalents, at Carrying Value	166,100	54,100
Money Market Funds [Member]
Short-term Investments
Cash Equivalents, at Carrying Value	68,956	91,281
US Government Corporations and Agencies Securities [Member]
Short-term Investments
Cash Equivalents, at Carrying Value	$ 10,977	$ 0

CASH EQUIVALENTS AND SHORT-TE30

CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS (Details 1) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Cash, Cash Equivalents, and Short-term Investments	$ 30,082	$ 0
US Treasury Securities [Member]
Cash, Cash Equivalents, and Short-term Investments	18,898	0
US Government Corporations and Agencies Securities [Member]
Cash, Cash Equivalents, and Short-term Investments	$ 11,184	$ 0

CASH EQUIVALENTS AND SHORT-TE31

CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS (Details 2) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Amortized Cost	$ 110,016	$ 91,281
Accretion	2
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(3)	0
Fair Value	110,015	91,281
US Government Debt Securities [Member]
Amortized Cost	22,161
Accretion	1
Gross Unrealized Gains	0
Gross Unrealized Losses	(1)
Fair Value	22,161
US Treasury Securities [Member]
Amortized Cost	18,900
Accretion	1
Gross Unrealized Losses	(2)
Fair Value	18,898
Money Market Funds [Member]
Amortized Cost	68,956	91,281
Accretion
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	$ 68,956	$ 91,281

BALANCE SHEET COMPONENTS (Detai

BALANCE SHEET COMPONENTS (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Accrued payroll and employee related expenses	$ 2,613	$ 2,613
Legal and related services	552	935
Clinical related	3,920	3,310
Manufacturing related	1,150	876
Deferred rent	363	430
Accrued other	388	496
Accrued liabilities	$ 8,986	$ 8,660

STOCKHOLDERS' EQUITY (Details)

STOCKHOLDERS' EQUITY (Details) - Warrant [Member] - USD ($)	6 Months Ended
STOCKHOLDERS' EQUITY (Details) - Warrant [Member] - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Shares Under Warrants
Outstanding, beginning balance	6,301,216
Issued	0
Exercised	(1,656,510)
Expired/Cancelled	0
Outstanding, ending balance	4,644,706
Weighted Average Exercise Price
Outstanding, beginning balance	$ 2.51
Granted	0
Exercised	2.50
Expired/Cancelled	0
Outstanding, ending balance	$ 2.51
Weighted Average Remaining Contractual Life
Outstanding	4 months 24 days
Aggregate Intrinsic Value
Outstanding, ending balance	$ 47,830,172	$ 34,651,188

STOCKHOLDERS' EQUITY (Details T

STOCKHOLDERS' EQUITY (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	6 Months Ended
	Jan. 31, 2018	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Class of Stock [Line Items]
Proceeds from Issuance of Common Stock		$ 162,093	$ 0
Shares Issued, Price Per Share	$ 11.50
Conversion of Stock, Shares Converted		1,250,549
Common Stock [Member]
Class of Stock [Line Items]
Conversion of Stock, Shares Converted		1,250,549
Common Stock [Member] \| Issuance Of Common Stock Upon Conversion Of Preferred Stock [Member]
Class of Stock [Line Items]
Conversion of Stock, Shares Issued		1,500
Conversion of Stock, Shares Converted		750,000
IPO [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues	15,000,000
Proceeds from Issuance of Common Stock	$ 162,000	$ 162,000
Shares Issued, Price Per Share	$ 11.50
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	1,956,521
Proceeds From Issuance Of Common Stock, Gross	$ 172,500
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Conversion of Stock, Shares Issued		500
Preferred Stock, Shares Authorized				17,000
Series A Convertible Preferred Stock [Member] \| Private Placement [Member]
Class of Stock [Line Items]
Sale of Stock, Price Per Share		$ 2
Preferred Stock, Par or Stated Value Per Share		$ 1,000
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Authorized		11,500,000		11,500,000
Preferred Stock, Par or Stated Value Per Share		$ 0.001		$ 0.001
Preferred Stock, Shares Outstanding		6,127,692		7,378,241
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Authorized		11,500,000
Preferred Stock, Par or Stated Value Per Share		$ 4.75
Convertible Price Per Shares		$ 4.75
Blank Check [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Authorized		50,000,000
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Authorized		17,000		17,000
Preferred Stock, Par or Stated Value Per Share		$ 0.001		$ 0.001
Preferred Stock, Shares Outstanding		194		1,694

STOCK BASED COMPENSATION (Detai

STOCK BASED COMPENSATION (Details) - Employee Stock Option [Member]	6 Months Ended
	Jun. 30, 2018USD ($)$ / sharesshares
Number of Options
Outstanding, beginning balance \| shares	6,072,368
Granted \| shares	2,014,020
Exercised \| shares	(895,153)
Expired/Forfeited \| shares	(353,418)
Outstanding, ending balance \| shares	6,837,817
Exercisable \| shares	2,791,279
Weighted Average Exercise Price
Outstanding, beginning balance \| $ / shares	$ 7.42
Granted \| $ / shares	15.67
Exercised \| $ / shares	7.63
Expired/Forfeited \| $ / shares	10.53
Outstanding, ending balance \| $ / shares	9.66
Exercisable \| $ / shares	$ 7.84
Weighted Average Remaining Contractual Life
Outstanding	8 years 7 months 2 days
Exercisable	7 years 10 months 6 days
Aggregate Intrinsic Value
Outstanding, ending balance \| $	$ 28,425,872
Exercisable \| $	$ 14,671,393

STOCK BASED COMPENSATION (Det36

STOCK BASED COMPENSATION (Details 1)	6 Months Ended
STOCK BASED COMPENSATION (Details 1)	Jun. 30, 2018	Jun. 30, 2017
Expected dividend yield	0.00%	0.00%
Maximum [Member]
Expected term (in years)	6 years 6 months	6 years 6 months
Expected volatility	200.28%	209.69%
Risk-free interest rate	2.97%	2.34%
Minimum [Member]
Expected term (in years)	5 years 1 month 17 days	5 years 1 month 17 days
Expected volatility	167.54%	190.46%
Risk-free interest rate	2.27%	1.77%

STOCK BASED COMPENSATION (Det37

STOCK BASED COMPENSATION (Details Textual) - USD ($) $ / shares in Units, $ in Thousands

1 Months Ended

3 Months Ended

6 Months Ended

Jun. 30, 2016

Aug. 31, 2013

Jun. 30, 2018

Jun. 30, 2017

Jun. 30, 2018

Jun. 30, 2017

Apr. 22, 2018

Aug. 16, 2016

Apr. 10, 2015

Nov. 30, 2014

Aug. 20, 2014

Aug. 01, 2014

Aug. 02, 2013

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized

$ 38,100

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition

2 years 2 months 8 days

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value

$ 4,600

$ 200

Share-based Compensation

$ 5,200

$ 3,000

$ 9,326

$ 6,589

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period

137,500

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value

$ 15.26

$ 6.83

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number

91,665

Restricted Common Stock [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Allocated Share-based Compensation Expense

$ 70

$ 300

$ 100

$ 900

Restricted Stock [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Allocated Share-based Compensation Expense

$ 500

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition

1 year 11 months 1 day

Restricted Stock [Member] | Chief Executive Officer [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period

550,000

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value

$ 5.87

First Anniversary [Member] | Restricted Stock [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

36 months

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period

137,500

Satisfaction Of Clinical Trial Milestones [Member] | Restricted Stock [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period

275,000

2014 Equity Incentive Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized

4,000,000

2,350,000

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant

906,390

2014 Equity Incentive Plan [Member] | Maximum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized

9,000,000

2014 Equity Incentive Plan [Member] | Minimum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized

4,000,000

2011 Equity Incentive Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant

542,490

Share-based Compensation Arrangement by Share-based Payment Award, Description

an amendment to increase the number options or other awards that can be granted to any one person during a twelve (12) month period from 50,000 shares to 300,000 shares.

Common Stock, Capital Shares Reserved for Future Issuance

1,900,000

1,700,000

180,000

2011 Equity Incentive Plan [Member] | Minimum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant

180,000

2018 Equity Incentive Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized

6,000,000

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant

6,000,000

Employee Stock Option [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period

895,153

116,348

LICENSES AND AGREEMENTS (Detail

LICENSES AND AGREEMENTS (Details Textual) - USD ($) $ in Thousands	Sep. 14, 2016	Apr. 17, 2017	Nov. 30, 2016	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2016	May 31, 2017
Research and Development Expense				$ 24,551	$ 18,647	$ 44,463	$ 34,240
Reversal of Prior Period Expense						400
Research and Development Arrangement [Member]
Prepaid Expense, Current									$ 1,400
Research Collaboration and Clinical Grant Agreements [Member]
Research and Development Expense				1,000	1,700	1,600	2,300
Strategic Alliance Agreement [Member]
Research and Development Expense				100		100
Maximum [Member] \| Research and Development Arrangement [Member]
Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross		$ 14,200
Karolinska University Hospital [Member]
Payments For Clinical Trials Agreement								$ 1,600
Proceeds from Refund of Clinical Trials Agreement						1,600
National Cancer Institute [Member]
Research and Development Expense						$ 500
Moffitt License Agreement [Member]
Agreement Term						20 years
Cooperative Research and Development Agreement [Member]
Research and Development Expense				500	500	$ 1,000	1,000
PolyBioCept, AB - Exclusive and Co-Exclusive License Agreement [Member]
Research and Development Expense				0	200	0	200
Payment For Upfront Exclusive License	$ 2,500
Additional Milesone Payable	$ 8,700
Number Of Unregistered Common Stock To Be Issued	2,219,376
ReimbursementIn Relation To Transfer Of Knowhow	$ 200
Clinical Trials Management Fees Payable	$ 100
Initial Term Of Licence Agreement	30 years
WuXi Apptech, Inc - Manufacturing and Services Agreement [Member]
Research and Development Expense				3,300	$ 3,300	6,000	$ 7,500
WuXi Apptech, Inc - Manufacturing and Services Agreement [Member] \| Manufacturing Suites [Member]
Manufacturing and Services Agreement, Amount Payable			$ 2,500
WuXi Apptech, Inc - Manufacturing and Services Agreement [Member] \| Commercial Manufacturing cGMP Suite [Member]
Manufacturing and Services Agreement, Amount Payable			$ 5,850
Moffitt License Agreement One [Member]
Payments For Upfront Licensing Fee						100
Moffitt License Agreement Two [Member]
Payments For Upfront Licensing Fee				100
Additional Milesone Payable				$ 400		$ 400

LEGAL PROCEEDINGS (Details Text

LEGAL PROCEEDINGS (Details Textual)	Jun. 13, 2017USD ($)shares	Jun. 03, 2016USD ($)	Nov. 30, 2012USD ($)	Jun. 30, 2012USD ($)	Sep. 30, 2016shares	Jun. 30, 2018USD ($)shares	Apr. 08, 2016USD ($)
Loss Contingency, Damages Sought, Value		$ 500,000
Common Stock Registered For Resale \| shares						128,500
Number of share options or share units exercised during the current period. \| shares						128,500
Dr. Steven Fischkoff [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross \| shares	150,000
Severance Pay And Retention Bonus	$ 300,000
Warrant [Member]
Shares Sold Under Ineffective Registration \| shares					128,500
Minimum [Member]
Loss Contingency, Estimate of Possible Loss							$ 1,500,000
Solomon Capital, LLC [Member]
Proceeds from Related Party Debt			$ 200,000	$ 100,000
Debt Instrument, Convertible, Number of Equity Instruments						111,425
Solomon Capital, LLC [Member] \| Commercial Paper [Member]
Debt Instrument, Face Amount						$ 200,000

COMMITMENTS AND CONTINGENCIES40

COMMITMENTS AND CONTINGENCIES (Details) $ in Thousands	Jun. 30, 2018USD ($)
2018 (remaining nine months)	$ 501
2,019	707
2,020	495
2,021	169
Total	$ 1,872

COMMITMENTS AND CONTINGENCIES41

COMMITMENTS AND CONTINGENCIES (Details Textual)	Aug. 04, 2016USD ($)ft²	Apr. 20, 2018USD ($)	Apr. 28, 2017USD ($)ft²	Sep. 30, 2016USD ($)ft²	Jun. 30, 2018USD ($)	Jun. 30, 2017USD ($)	Jun. 30, 2018USD ($)	Jun. 30, 2017USD ($)	Jun. 05, 2017USD ($)	Apr. 30, 2015ft²	Dec. 31, 2014ft²
License And Commitments [Line Items]
Operating Leases, Rent Expense		$ 7,000			$ 200,000	$ 200,000	$ 500,000	$ 500,000
Operating Leases, Future Minimum Payments Due					$ 1,872,000		1,872,000
Tampa Lease [Member]
License And Commitments [Line Items]
Area of Land \| ft²				8,673						6,043	5,115
Operating Leases, Rent Expense				$ 20,000
New York Lease [Member]
License And Commitments [Line Items]
Operating Leases, Future Minimum Payments Due									$ 9,000
Operating Leases, Rent Expense, Minimum Rentals							$ 18,000
San Carlos Lease [Member]
License And Commitments [Line Items]
Area of Land \| ft²	8,733
Lease Expiration Term	54 months
Operating Leases, Future Minimum Payments Due	$ 38,000
Operating Leases, Rent Expense, Sublease Rentals			$ 26,000
Teradata US, Inc [Member]
License And Commitments [Line Items]
Area of Land \| ft²			11,449

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Sep. 14, 2017	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Payments for Legal Services		$ 200			$ 200
Due to Related Parties, Current		300	$ 400	$ 300	400
Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award	The granted stock options vest in 12 quarterly installments (with 1/12th of the option shares having vested on the date of grant).
Share-based Compensation		5,200	$ 3,000	9,326	$ 6,589
Consulting Agreement [Member]
Share-based Compensation		$ 200		$ 600
Board of Directors Chairman [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	150,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 7.30